Better responses and longer survival than expected with conventional chemotherapy.
ONCOLOGY
Fully funded by 
Content independently selected
-
Merkel cell carcinoma: pembrolizumab boosts survival, tumor control -
Melanoma: 5-year pembrolizumab data from KEYNOTE-001 Findings show durable antitumor activity and tolerability.
-
H&N melanoma: postbiopsy pigmentation predicts shorter DFS Close surveillance warranted.
-
Melanoma: trametinib ups PFS, OS in METRIC 5-year follow-up Evidence for long-term benefit and safety in BRAF-positive disease.
-
Cutaneous SCC: immunosuppression tied to post-RT recurrence Majority of failures were salvaged surgically.
-
Melanoma: age predicts features of distant metastasis in German study Pattern, timing, and extent of distant metastasis change with age.
-
Melanoma: redefined T1b category may lead to excess SLNB More than half of T1b lesions without ulceration have low risk for positive SLN.
-
Amelanotic malignant melanoma: clinicopathologic features AMM is often challenging to diagnose.
-
Encorafenib with binimetinib approved for BRAF V600-positive melanoma It is estimated that approximately 858 people will be eligible to receive the treatment in year 1, rising to 972 in year 5
-
Ulceration tied to poor survival in thin melanoma California Cancer Registry data for 43,000 white patients.
-
Melanoma: CECT feature predicts OS, PFS with pembrolizumab in French study A useful tool for identifying candidates for pembrolizumab treatment.
-
Cochrane Review.
-
40 case reports of gastrointestinal-associated cytomegalovirus infection or reactivation with ipilimumab Patients on ipilimumab should be advised to contact their healthcare professional immediately at the onset of symptoms of colitis.
-
Imatinib found beneficial for DFSP in systematic review 55% partial response rate in locally advanced or metastatic disease.